TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Atrys Health SA ( (ES:ATRY) ) has provided an announcement.
Atrys Health SA has announced a succession plan involving the appointment of Marian Isach as the future CEO, succeeding Isabel Lozano, who will remain as a non-executive director. Santiago de Torres will transition to a non-executive chairman role. This plan reflects Atrys’ commitment to internal talent and governance best practices. The company also reported an 11.2% increase in revenue for the first quarter of 2025, driven by growth across all business areas, particularly in Oncology and Diagnosis.
More about Atrys Health SA
Atrys is a global healthtech company specializing in prevention, diagnosis, and precision treatment services, with a strong focus on telemedicine and cancer treatment. It has established itself as a leader in the Spanish-speaking telemedicine market and is a pioneer in high-precision oncological radiotherapy in Europe.
Average Trading Volume: 47,520
Technical Sentiment Signal: Strong Sell
Current Market Cap: €218.1M
Learn more about ATRY stock on TipRanks’ Stock Analysis page.